Get the Stockscreener App
1.62
1.25%
0.02
Cabaletta Bio Inc stock is traded at $1.62, with a volume of 797.27K.
It is up +1.25% in the last 24 hours and up +2.53% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$1.60
Open:
$1.62
24h Volume:
797.27K
Relative Volume:
0.39
Market Cap:
$148.17M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-0.9759
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
-5.26%
1M Performance:
+2.53%
6M Performance:
-21.36%
1Y Performance:
-72.07%
1-Day Range:
$1.595
$1.67
1-Week Range:
$1.5401
$1.8299
52-Week Range:
$0.9857
$6.26
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.62 | 161.89M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Resistance Break Could Fuel Cabaletta Bio Inc. Rally2025 Price Targets & Daily Stock Trend Watchlist - classian.co.kr
Heatmap Data Shows High Activity in Cabaletta Bio Inc. Sector2025 Valuation Update & Daily Profit Focused Screening - newsyoung.net
Published on: 2025-08-20 09:42:53 - beatles.ru
Myasthenia Gravis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma, Takeda - The Globe and Mail
Cabaletta Bio (CABA) Q2 Loss Widens 30% - AOL.com
Is Cabaletta Bio Inc. in Accumulation Phase Now2025 Macro Impact & Risk Controlled Swing Alerts - beatles.ru
Sentiment Tools Show Shift in Trader Mood on Cabaletta Bio Inc.2025 Sector Review & Community Driven Trade Alerts - beatles.ru
Why is Cabaletta Bio Inc. stock going upVolume Spike & Accurate Buy Signal Notifications - mustnews.co.kr
Is Cabaletta Bio Inc. stock a buy or sellWatch List & Risk Controlled Stock Alerts - mustnews.co.kr
Published on: 2025-08-15 22:30:57 - thegnnews.com
TD Cowen Maintains Cabaletta Bio(CABA.US) With Buy Rating - 富途牛牛
Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by Federated Hermes Inc. - MarketBeat
CABA.O Spikes Sharply—Was It a KDJ Golden Cross or Broader Biotech Rotation? - AInvest
Cabaletta Bio Surges 25.56% Amid Sector Turmoil: What's Fueling This Biotech's Rally? - AInvest
Evercore ISI Reaffirms Their Hold Rating on Cabaletta Bio (CABA) - The Globe and Mail
What makes Cabaletta Bio Inc. stock price move sharplyPrice Volume Breakout Screener - thegnnews.com
Cabaletta Bio shares fall 1.84% intraday due to lock-up agreements on stock options and warrants. - AInvest
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - Yahoo Finance
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Benzinga
Are Bears Losing Grip on Cabaletta Bio Inc.Real-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Cabaletta Bio shares rise 4.41% premarket as stock options lock-up agreement ends. - AInvest
Certain Stock Options of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2025. - MarketScreener
Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2025. - MarketScreener
Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears - MSN
Wells Fargo Adjusts Price Target for Cabaletta Bio to $2.00, Reflecting a 33.33% Decrease from $3.00. - AInvest
Guggenheim lowers Cabaletta Bio stock price target to $15 on dilution - Investing.com Canada
Jefferies lowers Cabaletta Bio stock price target to $14 from $28 - Investing.com Australia
Cabaletta Bio Reports Progress in Clinical Trials - TipRanks
Cabaletta Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Cabaletta Bio (CABA) Plans $240M Mixed Securities Offering - GuruFocus
Cabaletta Bio Files $240 Million Shelf Offering - MarketScreener
Cabaletta Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis - TipRanks
Cabaletta Bio Inc files for mixed shelf offering of up to $240 million- SEC filing - MarketScreener
Cabaletta Bio Q2 2025: RESET-Myositis trial enrollment to start in 2H25, BLA submission in 2027. - AInvest
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update | CABA Stock News - GuruFocus
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Cabaletta Bio’s Promising Study on CABA-201 for Myasthenia Gravis: A Potential Game-Changer - TipRanks
Individual investors who have a significant stake must be disappointed along with institutions after Cabaletta Bio, Inc.'s (NASDAQ:CABA) market cap dropped by US$17m - Yahoo Finance
Cabaletta Bio Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Published on: 2025-08-04 17:06:26 - beatles.ru
How does Cabaletta Bio Inc. compare to its industry peersUnlock expert market analysis instantly - Jammu Links News
What institutional investors are buying Cabaletta Bio Inc. stockRapidly expanding wealth - Jammu Links News
How does Cabaletta Bio Inc. generate profit in a changing economyInvest smarter with actionable trading signals - Jammu Links News
What analysts say about Cabaletta Bio Inc. stockAchieve remarkable returns with smart investing - Jammu Links News
Should I hold or sell Cabaletta Bio Inc. stock in 2025Sky-high return potential - Jammu Links News
What is the dividend policy of Cabaletta Bio Inc. stockTurn market volatility into profit opportunities - Jammu Links News
What drives Cabaletta Bio Inc. stock priceUnlock powerful market trend analysis - Jammu Links News
How volatile is Cabaletta Bio Inc. stock compared to the marketConsistently exceptional gains - Jammu Links News
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):